These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Assessment of bone quality. Bone quality and osteoporosis treatment]. Mashiba T Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816 [TBL] [Abstract][Full Text] [Related]
11. [Postmenopausal osteoporosis]. László A Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134 [TBL] [Abstract][Full Text] [Related]
12. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of osteoporosis by the gynecologist]. Schneider HP; Dören M Zentralbl Gynakol; 1994; 116(12):691-4. PubMed ID: 7846982 [TBL] [Abstract][Full Text] [Related]
14. [Combination therapy for osteoporosis]. Kishimoto H Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119 [TBL] [Abstract][Full Text] [Related]
15. [Treatment and prevention of osteoporosis in patients with decreased renal function]. Vestergaard P; Eiken PA Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452 [TBL] [Abstract][Full Text] [Related]
16. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228 [TBL] [Abstract][Full Text] [Related]
18. [Bone remodeling]. Lerner UH; Ljunggren O Lakartidningen; 2006 Oct 4-10; 103(40):2972-5. PubMed ID: 17115661 [No Abstract] [Full Text] [Related]
19. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. Ohta H Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041 [TBL] [Abstract][Full Text] [Related]
20. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Yosipovitch G; Hoon TS; Leok GC Arch Dermatol; 2001 Apr; 137(4):477-81. PubMed ID: 11295929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]